drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous genetically engineered T cells expressing a chimeric antigen receptor targeting GUCY2C; infused once after lymphodepletion to mediate HLA-independent cytotoxicity and cytokine release against GUCY2C-positive colorectal cancer cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a chimeric antigen receptor that binds GUCY2C on colorectal cancer cells, triggering HLA-independent T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxicity to kill GUCY2C-positive tumor cells; given after lymphodepletion to enhance expansion and persistence.
drug_name
IM96 CAR-T Cells
nct_id_drug_ref
NCT06718738